Her2/neu Immunogenic Composition

Abstract

The invention provides for an immunogenic composition comprising a. a directed adjuvant comprising at least an anti-CD32 moiety linked to a TLR9 ligand and a first peptidic alpha-helix; and b. an immunogen comprising an extracellular Her2/neu domain that is linked to a second peptidic alpha-helix coiled to the first alpha-helix; The invention further provides a kit for producing such immunogenic composition, a vaccine comprising such immunogenic composition and its medical use, such as for treating Her2/neu positive tumor diseases.


Claims
Download PDF
Document Preview
Document History
  • Publication: Nov 24, 2016
  • Application: May 17, 2016
    WO EP 2016061035 W
  • Priority: May 18, 2015
    EP EP 15168025 A

Download Citation


Sign in to the Lens

Feedback